JULIA GYAMPOH: Open Payments
NPI 1073986162 · CHARLOTTESVILLE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$567 in 18 payments from 10 companies in 2025. Trend: 2023 $480 · 2024 $221 · 2025 $567
Food & beverage: $567
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $173 |
| Janssen Biotech, Inc. | 2 | $82 |
| GlaxoSmithKline, LLC. | 3 | $78 |
| Novartis Pharmaceuticals Corporation | 2 | $52 |
| Daiichi Sankyo Inc. | 2 | $50 |
| PFIZER INC. | 1 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Merck Sharp & Dohme LLC | 1 | $28 |
| GENZYME CORPORATION | 1 | $22 |
| PUMA BIOTECHNOLOGY, INC. | 1 | $18 |
Products named: CALQUENCE, RYBREVANT, OJJAARA, IBRANCE, LIBTAYO, SCEMBLIX, KEYTRUDA, DATROWAY.
Industry payments across VA — which companies pay providers there.
